

Patient Card CARVYKTI[®]▼ (ciltacabtagene autoleucel)

PATIENT’S NAME:

Emergency Contact

PATIENT CARER’S NAME:

PATIENT CARER’S PHONE NUMBER:

FOLD HERE

Primary CAR-T Healthcare Professional

**HEALTHCARE
PROFESSIONAL’S NAME:**

**HEALTHCARE
PROFESSIONAL’S
PHONE NUMBER:**

CAR-T CENTRE ADDRESS:

**CAR-T CENTRE
PHONE NUMBER:**

FOLD HERE

Important Information for Patients

Carry this card with you at all times. Show it to any doctor who sees you and when you go to the hospital.

Tell any healthcare professional who sees you that you have been treated with ciltacabtagene autoleucel.

Plan to stay near the hospital where you were treated for at least 4 weeks after you have ciltacabtagene autoleucel.

Do not drive or use tools or machines until at least 8 weeks after ciltacabtagene autoleucel infusion.

Refer to the Patient Information Leaflet for more information.

FOLD HERE

If you experience any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare professional, or any healthcare professional available.

Ciltacabtagene autoleucel can cause serious side effects such as cytokine release syndrome and neurological toxicities. These symptoms can be life-threatening or even fatal and need to be addressed immediately.

Symptoms that appear mild may quickly worsen.

Symptoms may be delayed and may occur weeks after your infusion.

Call your treating healthcare professional straight away if you have any of these symptoms:

Cytokine release syndrome (CRS)

- Fever (38°C or higher)
- Chills
- Fast heart beat
- Difficulty breathing
- Feeling dizzy or lightheaded

Neurologic toxicity (including ICANS)

- Feeling confused
- Feeling less alert, disorientated, anxious or having memory loss
- Having difficulty speaking or slurred speech
- Slower movements or changes in handwriting

FOLD HERE

Information for Healthcare Team to Fill In

Please give this card to your CAR-T healthcare team to fill in the information and return to you.

ON (DATE) _____

this patient received ciltacabtagene autoleucel, which is a chimeric antigen receptor T cell therapy (CAR-T cell therapy) for multiple myeloma.

(BATCH ID) _____

FOLD HERE

Important Information for Healthcare Professionals

This patient has received an engineered autologous T-cell immunotherapy product that can lead to severe and even fatal CRS and neurologic toxicity. CRS may involve any organ system. Assess the patient for signs and symptoms of CRS and neurologic toxicity.

See Summary of Product Characteristics for full details.

FOLD HERE

Before providing any treatment, call the primary healthcare professional at the number on the front of the card.

This patient should not donate blood, organs, tissues or cells for transplantation.

Reporting of side effects: ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get directly via HPRA Pharmacovigilance. Website: www.hpra.ie. Side effects should also be reported to Janssen Sciences Ireland UC, a Johnson & Johnson Company, on +44 1494 567447 or at dsafety@its.jnj.com.